A Phase II Study Of Blood Stem Cell Mobilization With Intravenous Melphalan (60 MG/M2) + G-CSF In Patients With Multiple Myeloma
- Determine the safety and efficacy of melphalan when used with filgrastim (G-CSF) for
stem cell mobilization in patients with multiple myeloma.
- Analyze how this mobilization regimen affects parameters of stem cell (CD34+)
mobilization and collection in these patients.
- Determine how this mobilization regimen affects disease status and clonotypic (i.e.,
tumor cell) contamination in stem cell components in these patients.
OUTLINE: Patients undergo peripheral blood stem cell (PBSC) mobilization consisting of
melphalan IV on day 1 and filgrastim (G-CSF) subcutaneously beginning on day 2 and
continuing until PBSC collection is complete.
Patients are followed at 1 month.
PROJECTED ACCRUAL: A total of 11-32 patients will be accrued for this study within 2 years.
Primary Purpose: Treatment
Raymond L. Comenzo, MD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|